Evotec AG (Germany) signed a transaction agreement with Sanofi (France) to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives.
This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018. The transaction will be closed in the coming weeks and remains subject to customary approvals and conditions, including the approval by regulatory authorities in France.
Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives. Going forward, Evotec will engage in open collaborations with other pharmaceutical and biotechnology companies, foundations, academia and government agencies to further accelerate research in infectious diseases. The initial focus areas will be on antimicrobial resistance and superbug infections, Tuberculosis and Malaria, as well as the creation of novel antiviral therapies with new mechanisms of action.
As part of the transaction, Sanofi will pay €60 million upfront and will provide Evotec with additional, significant long-term funding to ensure the progression of the highly innovative anti-infectives portfolio. Sanofi will retain certain option rights on the development, manufacturing and commercialisation of the anti-infective products resulting from the licensed assets.
Evotec will add and integrate 100 highly qualified employees into its global drug discovery and development operations. The positions from Sanofi will be transferred with certain, specific long-term commitments of employment. Evotec will continue to operate in Lyon, taking advantage of the location’s scientific and medical excellence in infectious diseases.
Evotec is a drug discovery alliance progressing innovative product approaches with leading pharmaceutical and biotechnology companies. Evotec, headquartered in Hamburg, Germany, is a drug discovery alliance progressing innovative product approaches with leading pharmaceutical and biotechnology companies.
Sanofi, a French multinational pharmaceutical company, is focused on the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world’s largest producer of the latter through its subsidiary Sanofi Pasteur).